Concord Biotech Limited CC-Dec23.pdf · 2024-02-09
Sure. So, we are seeing good growth overall in the API business. There were certain spill overs of certain key molecules into the subsequent months because of certain reasons. And these were relatively high-volume sale numbers for different reasons, because of which it got spilled over into the subsequent quarter. But if I look at it from an overall perspective, we see good growth within the API segment. And talking about how the split is between the different therapeutic segments. On a 9-month basis, we have seen the dependency on the immunosuppressant portfolio going down by close to 3% than what it was last year. And much of that has been gained through our increase in sales in the oncology followed by the anti-infective segment and then the antifungal segment. So, we are seeing good growth in all the therapeutic segments. But as more molecules are coming in the newer therapeutic segments, which ex-immunosuppressant, there is more growth happening in that segment.
So, we don't give a geographical segmentation for the formulations. But yes, India and emerging markets are the key markets for us. We have limited presence in the regulated markets. And the India business for us has grown very well. Particularly, the transplant or the immunosuppressant division, because we've been there in that segment for now close to five, six years. And I would say that we are the only company right now, which is having the full integration right from API to formulation, supplying from USFDA approved facility with full BA/BE studies. So, our quality is of very high standards. And that's something that the doctors and the medical fraternity and the patients appreciate because of which we've been growing so aggressively in the India market. Of course, being all manufacturers, we are catering not only to the corporate hospitals, but also to the tenders. The critical care division of ours is also doing very well. And we are very optimistic that with own manufacturing coming in, over a medium-term perspective, we are going to see similar high level growth in the injectable once we become own manufacturing on some of the specialized injectable products.